CONSORT flow diagram.
ADVERSE EVENTS, MINOR, RECRUITMENT
For the two-way ANOVA analysis involving three groups, we determined the appropriate sample size using G*Power software (version 3.1.9.7) [Written informed consent was obtained from all subjects and the signed informed consent documents were kept on file. The protocol was approved by the Dankook University ethics committee (IRB number: DKU-2021-05-046) and it adhered to the tenets of the Declaration of Helsinki and its later amendments or comparable ethical standards. The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.The recruitment period for this study was from June 10 to July 14, 2021, and the follow-up period was from June 14, 2021 to September 10, 2021. No dropouts or adverse events were reported. Although our institutions ethics committee did not require clinical trial registration, the study was retrospectively registered. We attempted to register the study as a clinical trial in October 2022, and we were successfully retroactively registered in the registry on November 22, 2022. This study conformed the protocol exactly until the study completion, with no deviations in methodology and only minor changes to the research title.This clinical trial was registered with the Clinical Research Information Service (CRIS) of Republic of Korea approved by the WHO. Registration number: KCT0007924. Date registered: November 22, 2022, retrospectively registered. The authors confirm that all ongoing and related trials for this drug/intervention are registered.